Elevated intraocular pressure

Ophthalmic Agent, Antiglaucoma; Prostaglandin

Onset of action: Reduction of IOP: ~4 hoursPeak effect: Maximum reduction of IOP: ~8 to 12 hoursDistribution: Vd: 0.67 L/kgProtein binding: ~88%Metabolism: Undergoes oxidation, N-deethylation, and glucuronidation after reaching systemic circulation; forms metabolitesHalf-life elimination: IV: ~45 minutesTime to peak: ?10 minutesExcretion: Urine (?67%); feces (25%)

Hypersensitivity to bimatoprost or any component of the formulation.

According to the manufacturer, an increased risk of major birth defects or miscarriages has not been observed following use of bimatoprost in pregnant women. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus

It is not known if bimatoprost is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Increased growth in number of eyelashesConjunctival hyperemia, eye pruritus

Instill 1 drop into affected eye(s) once daily in the evening

Bimatoprost ophthalmic solution for the reduction of intraocular pressure is not recommended in children under the age of 16 years because of potential safety concerns related to increased pigmentation following chronic use